High cost oncology drugs without proof of added benefit are burdening health systems
Publication date
2024-02-29
Authors
Brinkhuis, Francine
Goettsch, Wim
Mantel-Teeuwisse, Aukje
Bloem, Lourens T
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Taverne, General Medicine
Citation
Brinkhuis, F, Goettsch, W G, Mantel - Teeuwisse, A & Bloem, L T 2024, 'High cost oncology drugs without proof of added benefit are burdening health systems', The BMJ, vol. 384, q511. https://doi.org/10.1136/bmj.q511